Outlook Therapeutics, Inc.OTLKNASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
100.00%
↑ 344% above average
Average (39q)
-40.98%
Historical baseline
Range
High:132.26%
Low:-831.40%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 100.00% |
| Q2 2025 | 63.33% |
| Q1 2025 | -308.33% |
| Q4 2024 | 132.26% |
| Q3 2024 | -83.77% |
| Q2 2024 | 123.85% |
| Q1 2024 | -831.40% |
| Q4 2023 | 14.00% |
| Q3 2023 | 37.89% |
| Q2 2023 | -209.62% |
| Q1 2023 | 67.50% |
| Q4 2022 | -18.52% |
| Q3 2022 | 15.63% |
| Q2 2022 | 11.11% |
| Q1 2022 | -12.50% |
| Q4 2021 | -0.63% |
| Q3 2021 | -13.57% |
| Q2 2021 | 19.54% |
| Q1 2021 | 26.58% |
| Q4 2020 | -8.22% |
| Q3 2020 | -231.82% |
| Q2 2020 | 90.83% |
| Q1 2020 | 41.94% |
| Q4 2019 | -75.64% |
| Q3 2019 | -82.90% |
| Q2 2019 | 80.31% |
| Q1 2019 | 2.00% |
| Q4 2018 | 19.32% |
| Q3 2018 | 40.98% |
| Q2 2018 | 21.05% |
| Q1 2018 | 53.17% |
| Q4 2017 | -175.19% |
| Q3 2017 | -17.27% |
| Q2 2017 | 35.29% |
| Q1 2017 | 58.70% |
| Q4 2016 | -77.51% |
| Q3 2016 | 71.01% |
| Q2 2016 | -697.76% |
| Q1 2016 | 83.07% |
| Q4 2015 | -3.72% |